Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration

Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best small cap stocks with biggest upside potential. On August 5, Janux Therapeutics announced a clinical milestone in its collaboration with Merck & Co. Inc. (NYSE:MRK), with the first patient being dosed in a lead program from their partnership. This achievement triggered a $10 million milestone payment to Janux.

The collaboration, which was established in December 2020, makes Janux eligible for additional development and commercial milestone payments, as well as royalties. Janux Therapeutics’ platforms are engineered to selectively modulate immune cells to fight cancer. A T cell engager is a type of bispecific antibody that brings T cells (a type of immune cell) and cancer cells into proximity, enabling the T cells to kill the cancer cells more effectively.

Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration

A rack of test tubes and beakers being stirred in a laboratory, as researchers analyze the data.

Janux’s technology is designed to overcome limitations of traditional T-cell engagers by being activated only within the tumor microenvironment, which aims to reduce toxicity and improve efficacy. Janux currently has two TRACTr candidates in Phase 1 clinical trials: JANX007, which targets prostate-specific membrane antigen/PSMA, and JANX008, which targets epidermal growth factor receptor/EGFR.

Janux Therapeutics Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company that develops immunotherapies based on Tumor Activated T Cell Engager/TRACTr and Tumor Activated Immunomodulator/TRACIr platforms technology to treat patients with cancer.

Merck & Co. Inc. (NYSE:MRK) is a healthcare company that operates through 2 segments: Pharmaceutical and Animal Health.

While we acknowledge the potential of JANX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JANX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.